#1 Clinical Trials Search in Europe

Omp10

This article explores the use of OMP10, a component of the innovative cancer vaccine EO4010, in clinical trials for patients with metastatic colorectal cancer. The study aims to evaluate the safety and effectiveness of OMP10 in combination with other cancer treatments, offering new hope for patients who have previously undergone treatment for this advanced form of cancer.

Table of Contents

What is EO4010?

EO4010 is a new type of cancer treatment called a therapeutic vaccine. It’s being developed to help patients with metastatic colorectal cancer (mCRC) who have already tried other treatments[1]. Metastatic colorectal cancer means that cancer which started in the colon or rectum has spread to other parts of the body.

This vaccine is made up of several components, including substances called UCP2, EO2317, EO2318, OMP10, OMP11, and OMP12[1]. These are microbial-derived peptides, which means they’re small proteins derived from microorganisms. The vaccine is given as an injection under the skin (subcutaneous injection)[1].

How Does EO4010 Work?

EO4010 is designed to stimulate the body’s immune system to fight cancer cells. It works by:

  1. Teaching the immune system to recognize specific proteins (called tumor-associated antigens or TAAs) that are found on colorectal cancer cells[1].
  2. Activating immune cells, particularly T cells, to attack these cancer cells[1].

In the clinical trial, EO4010 is being tested alone and in combination with other cancer drugs:

  • Nivolumab: This is an immune checkpoint inhibitor that helps the immune system fight cancer more effectively[1].
  • Bevacizumab: This drug works by stopping the growth of new blood vessels that feed tumors[1].

Who Is EO4010 For?

EO4010 is being studied for patients who meet the following criteria:

  • Adults (18 years or older) with advanced colorectal cancer that can’t be surgically removed[1].
  • Patients whose cancer has continued to grow despite previous treatments, or who are not suitable for standard treatments[1].
  • Patients with a specific genetic marker called HLA-A2[1]. This is important because the vaccine is designed to work with this particular immune system type.
  • Patients whose cancer is mismatch repair proficient and microsatellite stable. These are characteristics of the tumor that affect how it might respond to treatment[1].

The AUDREY Clinical Trial

EO4010 is currently being tested in a clinical trial called AUDREY. This is a Phase 1/2 trial, which means it’s an early-stage study focusing on safety and initial effectiveness[1]. Here are some key points about the trial:

  • It’s a global study taking place at multiple medical centers[1].
  • The trial is divided into different groups (cohorts) to test EO4010 alone and in combination with other drugs[1].
  • Patients will receive regular treatments and check-ups for up to 43 weeks[1].
  • After treatment ends, patients will have follow-up visits to monitor their health and cancer status[1].

Potential Benefits of EO4010

While it’s important to remember that EO4010 is still in the testing phase, researchers hope it might offer several benefits:

  • A new treatment option for patients who have already tried standard therapies[1].
  • Potential to stimulate the immune system to fight cancer more effectively[1].
  • Possible improved outcomes when combined with other cancer treatments[1].

The trial will measure several outcomes to determine if EO4010 is effective, including:

  • Objective response rate (ORR): How many patients’ tumors shrink or disappear[1].
  • Disease control rate (DCR): How many patients’ cancers stop growing or shrink[1].
  • Progression-free survival (PFS): How long patients live without their cancer getting worse[1].
  • Overall survival (OS): How long patients live overall[1].

Possible Side Effects

As with any medical treatment, EO4010 may cause side effects. The main goal of the AUDREY trial is to assess the safety and tolerability of EO4010[1]. The researchers will carefully monitor patients for any adverse events, which could include:

  • Reactions at the injection site
  • Immune-related side effects
  • Any unexpected reactions when combined with other drugs

It’s important to note that all potential side effects are not yet known, as this is an early-stage trial. Patients in the trial will be closely monitored and should report any unusual symptoms to their healthcare team[1].

Aspect Details
Study Drug EO4010 (containing OMP10)
Condition Metastatic colorectal cancer
Study Design Phase 1/2 multicenter trial
Combination Therapies Nivolumab and/or Bevacizumab
Primary Objective Evaluate safety and tolerability
Secondary Objectives Assess immunogenicity, tumor response, survival outcomes
Eligibility HLA-A2 positive, previously treated, advanced colorectal cancer patients
Study Structure Multiple cohorts testing different drug combinations

FAQ

  • What is OMP10 and how is it being used in clinical trials? OMP10 is one of the active substances in EO4010, a novel cancer vaccine therapy being tested in clinical trials. It is being studied in combination with other drugs like nivolumab and bevacizumab for treating patients with metastatic colorectal cancer who have already received previous treatments.
  • Who is eligible to participate in this clinical trial? Eligible participants are HLA-A2 positive patients aged 18 or older with advanced non-resectable colorectal adenocarcinoma that is mismatch repair proficient and microsatellite stable. They must have been previously treated with standard therapies or are not considered candidates for such therapies.
  • What are the main objectives of this clinical trial? The primary objective is to evaluate the safety and tolerability of EO4010 (which contains OMP10) in combination with nivolumab and/or bevacizumab. Secondary objectives include assessing immunogenicity, tumor response rates, and survival outcomes.
  • How is the clinical trial structured? The trial is divided into different cohorts. Cohort 1 evaluates EO4010 alone, followed by combination with nivolumab. Cohort 2 tests EO4010 with nivolumab. Cohort 3 examines EO4010 with nivolumab and bevacizumab or just bevacizumab. Patients will be monitored during treatment and follow-up periods.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a novel cancer therapy that may help fight metastatic colorectal cancer. Risks may include side effects from the treatment combinations. The trial closely monitors patients' safety and well-being throughout the study period.

Ongoing Clinical Trials on Omp10

  • Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Spain

Glossary

  • Metastatic colorectal cancer: Cancer that has spread from the colon or rectum to other parts of the body.
  • EO4010: A novel microbial-derived peptide therapeutic vaccine being tested in clinical trials for colorectal cancer treatment.
  • OMP10: One of the active substances in the EO4010 vaccine.
  • Nivolumab: An immunotherapy drug that helps the immune system fight cancer cells.
  • Bevacizumab: A targeted therapy that blocks the growth of blood vessels that feed tumors.
  • HLA-A2: A specific type of human leukocyte antigen, which is important for the immune system's ability to recognize foreign substances.
  • Mismatch repair proficient: A characteristic of cancer cells that can effectively repair DNA mismatches, making them less responsive to certain treatments.
  • Microsatellite stable: A feature of cancer cells that do not have high levels of genetic instability in certain repeated DNA sequences.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.

References

  1. http://clinicaltrials.eu/trial/study-on-eo4010-vaccine-with-nivolumab-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer-who-have-already-received-treatment/